Tirzepatide

Mounjaro · Zepbound

GLP-1 Receptor Agonist GLP-1 Weight Loss SubQ FDA/EMA Label

Half-life

5 days

Time to Peak

24 hr

Steady State

~25 days

Bioavailability

80%

Dose Range

2.5–15 mg

Frequency

Weekly

Overview

Once-weekly injectable dual GIP/GLP-1 receptor agonist for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Demonstrated up to ~21% weight loss in SURMOUNT trials.

Mechanism of Action

Dual GIP and GLP-1 receptor agonist. First-in-class twincretin that activates both incretin receptors for enhanced glycemic control and weight loss.

Dosing Information

Route Dose Range Half-life Tmax Frequency
Subcutaneous (SubQ) 2.5–15 mg 5 days 24 hr Weekly

Storage & Handling

2-8C — Refrigerate unused pens. Can store at room temp (up to 30C) for up to 21 days. Do not freeze.

Used in Regimens

3 regimens

Data Sources

Related Tools

Track Tirzepatide with Doseline

Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.

Join the waitlist

Doseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.

Doseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.